As partner of the TRANSVAC-DS consortium, Flanders Vaccine contributes to the design and establishment of a sustainable European vaccine infrastructure.
TRANSVAC-DS (Design study for a European vaccine infrastructure), funded by the European Commission (EC) started on 01 June 2020 and is being coordinated by the European Vaccine Initiative. It is a consortium of 25 partner organisations from across eleven European countries.
TRANSVAC-DS builds on the outstanding successes of TRANSVAC1 and TRANSVAC2 projects (www.transvac.org), and the ultimate goal is the establishment of a sustainable pan-European Research Infrastructure bringing together leading European scientific expert groups with their state-of-the-art resources that will accelerate the development of safe, effective and affordable vaccines for global public health.
TRANSVAC will set up a diverse portfolio of vaccine projects in which you can invest.
A project leaflet is available with further information.
Flanders Vaccine contributes in several work packages, including ‘gaps and needs’ analysis of the research infrastructure landscape, stakeholder engagement and establishment of a suitable business model. We are also work package leader of WP6 ‘Communication & Dissemination’.
Further information about TRANSVAC-DS is available here. https://www.transvac.org/transvac-ds
Quick facts about TRANSVAC-DS:
Start Date: 01 June 2020
End Date: 31 May 2022
Coordinator: European Vaccine Initiative (EVI)
Project Funder: European Commission, Grant Number 951668
Total Funding: 1.88M EUR